Mayo-Wilson Evan, Hutfless Susan, Li Tianjing, Gresham Gillian, Fusco Nicole, Ehmsen Jeffrey, Heyward James, Vedula Swaroop, Lock Diana, Haythornthwaite Jennifer, Payne Jennifer L, Cowley Theresa, Tolbert Elizabeth, Rosman Lori, Twose Claire, Stuart Elizabeth A, Hong Hwanhee, Doshi Peter, Suarez-Cuervo Catalina, Singh Sonal, Dickersin Kay
Center for Clinical Trials and Evidence Synthesis, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD, 21205, USA.
Department of Gastroenterology and Hepatology, Johns Hopkins School of Medicine, 600 North Wolfe Street, Blalock 449, Baltimore, MD, 21287, USA.
Syst Rev. 2015 Nov 2;4:143. doi: 10.1186/s13643-015-0134-z.
Systematic reviews should provide trustworthy guidance to decision-makers, but their credibility is challenged by the selective reporting of trial results and outcomes. Some trials are not published, and even among clinical trials that are published partially (e.g., as conference abstracts), many are never published in full. Although there are many potential sources of published and unpublished data for systematic reviews, there are no established methods for choosing among multiple reports or data sources about the same trial.
We will conduct systematic reviews of the effectiveness and safety of two interventions following the Institute of Medicine (IOM) guidelines: (1) gabapentin for neuropathic pain and (2) quetiapine for bipolar depression. For the review of gabapentin, we will include adult participants with neuropathic pain who do not require ventilator support. For the review of quetiapine, we will include adult participants with acute bipolar depression (excluding mixed or rapid cycling episodes). We will compare these drugs (used alone or in combination with other interventions) with placebo or with the same intervention alone; direct comparisons with other medications will be excluded. For each review, we will conduct highly sensitive electronic searches, and the results of the searches will be assessed by two independent reviewers. Outcomes, study characteristics, and risk of bias ratings will be extracted from multiple reports by two individuals working independently, stored in a publicly available database (Systematic Review Data Repository) and analyzed using commonly available statistical software. In each review, we will conduct a series of meta-analyses using data from different sources to determine how the results are affected by the inclusion of data from multiple published sources (e.g., journal articles and conference abstracts) as well as unpublished aggregate data (e.g., "clinical study reports") and individual participant data (IPD). We will identify patient-centered outcomes in each report and identify differences in the reporting of these outcomes across sources.
CRD42015014037 , CRD42015014038.
系统评价应为决策者提供可靠的指导,但试验结果和结局的选择性报告对其可信度构成了挑战。一些试验未被发表,甚至在部分发表的临床试验(如会议摘要)中,许多也从未全文发表。尽管系统评价有许多已发表和未发表数据的潜在来源,但对于同一试验的多个报告或数据来源,尚无既定的选择方法。
我们将按照医学研究所(IOM)的指南,对两种干预措施的有效性和安全性进行系统评价:(1)加巴喷丁治疗神经性疼痛;(2)喹硫平治疗双相抑郁。对于加巴喷丁的评价,我们将纳入不需要呼吸机支持的成年神经性疼痛患者。对于喹硫平的评价,我们将纳入急性双相抑郁的成年患者(不包括混合发作或快速循环发作)。我们将这些药物(单独使用或与其他干预措施联合使用)与安慰剂或单独使用相同干预措施进行比较;排除与其他药物的直接比较。对于每项评价,我们将进行高度敏感的电子检索,检索结果将由两名独立的评审员进行评估。结局、研究特征和偏倚风险评级将由两名独立工作的人员从多个报告中提取,存储在一个公开可用的数据库(系统评价数据储存库)中,并使用常用的统计软件进行分析。在每项评价中,我们将使用来自不同来源的数据进行一系列荟萃分析,以确定纳入多个已发表来源(如期刊文章和会议摘要)以及未发表的汇总数据(如“临床研究报告”)和个体参与者数据(IPD)的数据如何影响结果。我们将在每份报告中确定以患者为中心的结局,并确定这些结局在不同来源报告中的差异。
CRD42015014037,CRD42015014038。